Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

By A. Calon, E. Lonardo, A. Berenguer-Llergo, Elisa Espinet, Xavier Hernando-Momblona, M. Iglesias, Marta Sevillano, Sergio Palomo-Ponce, Daniele V. F. Tauriello, Daniel Byrom and 9 more. Nature Genetics, 2015

1,012 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/9c547805578bce24b5440a5b8d0a6dc52a6d7a3e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

In Pathology and Forensic Medicine

J. Massagué

Citations in the corpus

In search of definitions: Cancer‐associated fibroblasts and their markers (2019, background): “A number of studies have already been conducted in order to identify the various CAF subtypes that reside within the overall tumor microenvironment.(23,33,56,89,90,96) These subtypes have been shown to possess extreme variability in regards to their marker expression, with certain subtypes showing a”
Inflammation and Cancer: Triggers, Mechanisms and Consequences (2019, background): “Moreover, IL-11 is involved in the recruitment of TGFβ driven and producing fibroblasts, which supports tumor invasion and immune escape in the subset of colon cancer with the worst clinical prognosis (Calon et al., 2012; Calon et al., 2015).”
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment (2018, background): “In human colorectal tumors, a similar mesenchymal signature, associated with a bad outcome, is characterized by a proinflammatory, proangiogenic, and immunosuppressive microenvironment with high lymphocyte and myeloid cell infiltration (46, 47).”
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression (2016, background): “These observations, largely consistent with the published literature [1, 4, 6, 7], validate the”
Dynamic EMT: a multi‐tool for tumor progression (2021, positive): “…non-small-cell lung cancer (NSCLC), activation of the AXL receptor tyrosine kinase in the course of EMT provides resistance to EGFR and PI3K inhibition, dependent on sustained KRAS activity (Singh et al , 2009; Sequist et al , 2011; Zhang et al , 2012; Byers et al , 2013; Tulchinsky et al , 2019).”
Transforming Grown Factor-β Signaling in Immunity and Cancer (2019, positive): “Elevated TGF-β levels produced by CAFs and other TME cell types exclude CD4+ and CD8+ T cells from the tumor center (Tauriello et al., 2018).”